Dart NeuroScience LLC is a private company headquartered in San Diego, CA, that develops drugs to improve memory. Kenneth E. Johns is currently the CEO of the firm.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Milkhaus Laboratory, Inc. provides organic chemical products. Its products are used for urological health, skin care, wound care and other healthcare concerns. The company develops drugs based on the theory of systemic signaling, which postulates that therapeutic molecules can send genomic or cellular signals that disrupt the dysfunctional signals causing disease and allow the body to restore healthy signals. Milkhaus Laboratory was founded by Robert W. Middleton in 1993 and is headquartered in Providence, RI.

Sangamo BioSciences is a clinical stage biopharmaceutical company involved in gene therapy that is researching ways of commercializing Zinc finger nucleases which modify a cell's DNA at an exact location thereby correcting or disrupting a specific gene. Sangamo BioSciences' lead therapy, SB-728, is a potential functional cure for HIV/AIDS. SB-728 works by removing some of the immune cells from the patient's blood that HIV attacks. The blood is sent to a lab which applies the SB-728 treatment to the patient's immune cells. The treatment removes the protein gateway on the immune cells that HIV needs to infect. The treated cells are then infused back into the patient whereby they reproduce and take over as HIV attacks and kills the non-treated cells. The treated, resistant cells thereby control the HIV infection and thus cures the patient from opportunistic infections that result from HIV. Recent published data further support the company's ongoing progress which has been described as "a major step toward immunological functional control of HIV."

MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases. Its therapies include paired vagus nerve stimulation system (Paired VNS System) and wireless neurostimulation system for the treatment of chronic pain, post-stroke upper limb mobility issues, and various neurological indications that enable healthcare practitioners to treat post-stroke upper limb mobility issues. Founded in 2007, MicroTransponder is headquartered in Dallas, Texas.

Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Helicon Therapeutics is a privately held Company formed to discover therapeutics to treat disorders of cognition through an understanding of the genetic basis of long-term memory formation. The scientific origin and founding intellectual property came from the neuroscience program at the Cold Spring Harbor Laboratory. Through seminal studies of learning and memory in fruit flies, a key function of the CREB (cAMP Response Element Binding Protein) gene was defined for the first time. The CREB gene encodes a protein which regulates the biochemical pathway that converts short-term memory to long-term memory - and it appears to function similarly in both fruit fly and in man. Further functional genomic studies have identified a large number of additional genes that participate in this (and parallel) memory pathway(s). All of these genes are potential targets for the production of drugs that enhance or diminish memory formation.

Oxford Biomedica (UK) Ltd., part of Oxford Biomedica Plc, is a company headquartered in Oxford, UK. The firm develops novel gene therapy products and treatment for cystic fibrosis.

SanBio, Inc. develops regenerative therapies for neurological disorders. The firm is focused on cell therapies for neurological disorders such as stroke, traumatic brain injury, eye disease, and Parkinson's disease. Its product pipeline includes SB623 and SB618. The company was founded by Keita Mori and Toru Kawanishi in 2001 and is headquartered in Mountain View, CA.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

National Rehabilitation Center is a Korean public health agency that oversees treatment, rehabilitation research, education and training.

Yuesai Biotechnology is a cell therapy drug developer that uses human pluripotent stem cell technology. Yuesai Biotechnology develops stem cell therapy for neurodegenerative diseases, rare diseases, and tumors using its proprietary intellectual property rights of human pluripotent stem cell preparation, cultivation, differentiation, and gene editing technology platform.

Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD.

Charcot-Marie-Tooth Association is an American private company that operates as a non profit organization.\nThe company says this about itself: CMT is a progressive neuromuscular disease affecting 1 in 2500 people worldwide, with early signs including high arched feet, curled toes, and claw-like hands. Many of these signs begin subtly and may go undiagnosed for years, leading to legs and arms becoming deformed and difficult to use. Those with CMT often lose the ability to walk and may become dependent upon assistive devices to remain mobile. There is no cure. To date, over 100 mutated genes associated with CMT have been identified, with more being discovered each year.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Khymeia Srl is a private company headquartered in Padua, Italy, that manufactures rehabilitation devices.